Download - William Tremaine CV
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Curriculum VitaeWilliam J. Tremaine, MD
1. Personal Information
2. Present Academic Rank and PositionConsultant - Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
07/1981 - Present
Professor of Medicine - Mayo Clinic College of Medicine 07/2001 - Present
3. EducationVanderbilt University - BA 1972
University of Mississippi, Jackson - MD 1976
Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Resident 1976 - 1979
Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Gastroenterology
1979 - 1981
4. CertificationsBoard Certifications
American Board of Internal Medicine (ABIM)
Internal Medicine 1979 - Present
Internal Medicine 1981 - Present
National Board of Medical Examiners (NBME)
Diplomate 1977 - Present
5. LicensureMinnesota 23670 (Medical) 01/1977 - Present
6. Honors/AwardsMerck Award - University of Mississippi Medical Center School of Medicine 01/1976J. Arnold Bargen Award for Outstanding Achievement as a Subspecialty Trainee in Gastroenterology - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
01/1981
Certificate of Appreciation: Drug Evauations - American Medical Association 01/1991Henry S. Plummer Distinguished Physician Award - Department of Internal Medicine, Mayo Clinic
01/2002
Mayo Clinic Distinguished Clinician Award - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
01/2007
Endowed Professorship, the Maxine and Jack Zarrow Professor of Medicine - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
01/2008
Maxine and Jack Zarrow Professorship 01/2008American Gastroenterological Association Fellowship - American Gastroenterological Association
01/2010
7. Military Service8. Previous Professional Positions and Major Appointments
Assistant Professor of Medicine - Mayo Clinic College of Medicine 07/1981 - 07/1995Associate Professor of Medicine - Mayo Clinic College of Medicine 07/1995 - 07/2001
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
9. Professional & Community Memberships, Societies and ServicesProfessional Memberships & ServicesPhi Eta Sigma National Honor Society
Member 01/1976 - PresentAlpha Omega Alpha Honor Medical Society
Member 01/1976 - PresentAmerican College of Physicians
Member 01/1979 - PresentFellow 01/1988
American Gastroenterological AssociationMember 01/1981 - Present
Sigma Xi, The Scientific Research SocietyMember 01/1987 - Present
Crohn's and Colitis Foundation of AmericaMember 01/1990 - PresentMember 01/2001 - Present
Professional Education CommitteeMember 01/1993 - PresentChair 01/1993 -
12/1996National Scientific Advisory Committee
Member 01/1993 - 12/1999
Minnesota ChapterMember 01/1993 - PresentBoard of Directors
Member 01/1993 - 12/1999
Professional Affairs CommitteeMember 01/1996 - PresentChair 01/1996 -
12/1999American Medical Association
Member 01/1993 - PresentMinnesota Medical Association
Member 01/1993 - PresentInflammatory Bowel Diseases Forum Committee
Member 01/1994 - PresentU.S. Department of Veterans Affairs
Veteran's AdministrationGrant Reviewer 01/1997 - PresentMember 01/1997 - Present
Food and Drug AdministrationMember 01/1998 - Present
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Gastrointestinal Drugs Advisory CommitteeVoting Member 01/1998 - PresentMember 01/1998 - Present
The Wellcome TrustGrant Reviewer 01/2000 - PresentMember 01/2000 - Present
American Board of Internal MedicineGastroenterology Subspecialty Board
Member 10/2012Journal Editorial ResponsibilitiesJournal of Clinical Gastroenterology
Associate Editor 01/1992 - 12/1992
Inflammatory Bowel DiseasesEditorial Board Member 01/1994 - Present
Mayo Clinic ProceedingsEditorial Board Member 01/1998 - PresentAssociate Editor 01/2001 - Present
Mayo Health O@sisInternet Web Site
Editorial Board Member 01/1998 - PresentAlimentary Pharmacology & Therapeutics
Editorial Board Member 01/1999 - PresentJournal Other ResponsibilitiesGastroenterology
Ad Hoc ReviewerMayo Clinic Proceedings
Ad Hoc ReviewerReviewer 01/1998 - Present
Journal of the American Medical AssociationAd Hoc Reviewer
American Journal of GastroenterologyAd Hoc Reviewer
Southern Medical JournalAd Hoc Reviewer
Journal of Laboratory and Clinical MedicineAd Hoc Reviewer
European Journal of GastroenterologyAd Hoc Reviewer
Diseases of the Colon and RectumAd Hoc Reviewer
Journal of Clinical GastroenterologyReviewer 01/1992 - Present
Inflammatory Bowel Diseases
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Reviewer 01/1994 - PresentMayo Health O@sis
Reviewer 01/1998 - PresentInternet Web Site
Reviewer 01/1998 - PresentAlimentary Pharmacology & Therapeutics
Reviewer 01/1999 - Present
10. Educational ActivitiesA. Curriculum/Course DevelopmentB. Teaching
Intestinal Malabsorption Mayo Graduate School Rochester, Minnesota
01/1982 - 12/1989
Protein Digestion and Metabolism Mayo Medical School Rochester, Minnesota
01/1983 - 12/1992
Mayo Clinic Update in Gastroenterology Maui, Hawaii
1985
Physical Diagnosis Mayo Medical School Rochester, Minnesota
01/1985 - 12/1991
Mayo Clinic Update in Gastroenterology Buena Vista, Florida
1987
Selected Topics in Internal Medicine Mayo Clinic Scottsdale, Arizona
1988
Mayo Clinic Update in Gastroenterology St. Petersburg, Florida
1989
Enterostomal Therapy Symposium Mayo Clinic Rochester, Minnesota
1989
Internal Medicine Course Mayo Clinic Rochester, Minnesota
1989
Mayo Clinic Advances in Diagnostic Radiology Tucson, Arizona
1990
Mayo Clinic Postgraduate Course San Diego, California
1991
Inflammmatory Bowel Disease: Clinical Update Course Director, Mayo Division of Gastroenterology Continuing Education Course Mayo Clinic Rochester, Minnesota
1992
Mayo Continuing Education: Practice of Internal Medicine Mayo Clinic Rochester, Minnesota
1992
Inflammmatory Bowel Disease: Clinical Update Course Director, Combined Mayo Foundation and Crohn's and Colitis Foundation
1993
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
of America Continuing Education Course Mayo Clinic Rochester, Minnesota
Medical Management of IBD Division of Colorectal Surgery Rochester, Minnesota
1995
Dysplasia in IBD Division of Colorectal Surgery Rochester, Minnesota
1996
Update on the Medical Treatment of IBD Division of Colorectal Surgery Rochester, Minnesota
01/1997 - 12/1999
IBD Update Course Director Mayo Clinic Rochester, Minnesota
01/1998 - 01/2002
A New Millennium in Gastroenterology Mayo Clinic Kohala, Hawaii
1999
C. MentorshipIndividual and Position Timeframe &
DescriptionOutcomes Current Status
D. Academic Career Development
11. Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other ActivitiesMayo ClinicMayo Clinic Committees
Institutional Review BoardMember 01/2002Administrative Committee
DirectorHospital Policy Committee
Member 01/1992 - 12/1993
Mayo Clinic Task Forces/Work GroupsInflammatory Bowel Disease Clinic
Director 01/1991 - Present
Member 01/1991 - Present
Department of Education AdministrationMayo Clinic College of Medicine
Mayo School of Continuous Professional DevelopmentMember 01/1992 -
PresentContinuing Medical Education
Member 01/1992 - Present
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Inflammatory Bowel Disease: Clinical UpdateMember 01/1992 -
PresentProgram Director 01/1992 -
12/1992Program Director 01/1993 -
12/1993Mayo Foundation for Medical Education and Research
Director 01/2002Member 01/2002
Mayo Clinic in RochesterDepartment of Internal Medicine
Member 01/1981Internal Medicine Resident Advisory Committee
Member 01/1981 - 12/1993
Division of Gastroenterology and HepatologyMember 01/1981Recruitment Committee
Member 01/1985 - 12/1990
Executive CommitteeMember 01/1990 -
12/1993GI Division Subspecialty Directors Committee
Member 01/1991 - Present
Research CommitteeMember 01/1993 -
12/1998Mayo Clinic Rochester Committees
Mayo Clinic Transfusion CommitteeMember 01/1982 -
12/1986
12. Presentations ExtramuralNational/International
Invited
Franciscan Medical Center Rock Island, Illinois
1987
Syrian Society of Gastroenterology Meeting Damascus, Syrian Arab Republic
1988
University Hospital Aleppo, Syrian Arab Republic
1988
Indian Society of Gastroenterology National Meeting Bangalore, India
1989
Inflammatory Bowel Disease Symposium 1990
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Birmingham, Alabama
Allen Memorial Hospital Waterloo, Iowa
1991
St. Olaf Hospital Austin, Minnesota
1991
Malaysin Society of Gastroenterology and Hepatology Kuala Lumpur, Malaysia
1992
Pouchitis 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis Munich, Germany
1997
Butterworth Hospital Grand Rapids, Michigan
1997
Cleveland Clinic Division of Gastroenterology Cleveland, Ohio
1998
Conventional therapy for Crohns disease Annual Meeting of the American Gastroenterological Association Orlando, Florida
1999
Pouchitis - The key of IBD etiology? International Symposium, 30 years with the ileal pouch Goteborg, Sweden
1999
Ulcerative colitis - The doctor in focus Montreuxs, Switzerland
2002
Gastrointestinal events review board Cape Town, South Africa
2002
Evolving approaches to IBD Salt Lake City, Utah
2002
Update on inflammatory bowel disease Tulsa, Oklahoma
2002
New strategies in IBD therapy Denver, Colorado
2002
New strategies in IBD therapy Birmingham, Michigan
2002
Innovations in the management of IBD New Orleans, Louisiana
2002
Digestive Disease Week India Cochin, India
2002
Innovations in the management of IBD Jackson Jackson, Mississippi
2002
IBD Meeting New Zealand Society of Gastroenterology Waihekee, New Zealand
2002
Oral
Lecturer Cedars Sinai Medical Center Symposium
1983
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Los Angeles, California
Update on Gastrointestinal Disease Mercy Hospital Medical Center Des Moines, Iowa
1984
Oral Mesalamine Symposium London, United Kingdom
1987
Minnesota Academy of Family Physicians Minneapolis, Minnesota
1990
Inflammatory Bowel Diseases - Pathophysiology as Basis of Treatment Falk Symposium Regensburg, Germany
1992
Update in Internal Medicine: University of Utah Snowbird, Utah
1992
Moderator, Inflammatory Bowel Disease Therapy Oral Presentations American Gastroenterological Association Research Forum Boston, Massachusetts
1993
Moderator, Infalmmatory Bowel Disease Therapy Oral Presentations American Gastroenterological Association New Orleans, Louisiana
1994
Greater New Jersey Crohn's and Colitis Symposium Plainfield, New Jersey
1994
Inflammatory Bowel Disease Symposium. University of Louisville. Louisville, Kentucky
1994
Reaching For a Cure Medical Symposium. Crohn's and Colitis Foundation Birmingham, Alabama
1994
Reaching For a Cure Medical Symposium. Crohn's and Colitis Foundation Tampa, Florida
1994
Panelist, Case Management of Inflammatory Bowel Disease University of Chicago Chicago, Illinois
1994
Moderator, Inflammatory Bowel Disease Therapy Oral Presentations American Gastroenterology Association San Diego, California
1995
Moderator, Inflammatory Bowel Disease Therapy Oral Presentations American Gastroenterology Association San Francisco, California
1996
Update on Inflammatory Bowel Disease Genesee Hospital Rochester, New York
1996
New directions in anti-inflammatory therapy for IBD Immunological Disorders of the Intestines Symposium Buenos Aires, Argentina
1996
Immunotherapy for IBD: Conventional agents Immunological Disorders of the Intestines Symposium Buenos Aires, Argentina
1996
Immunotherapy for IBD: Experimental agents Immunological Disorders of the Intestines Symposium
1996
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Buenos Aires, Argentina
Antimicrobial and nutritional therapy for IBD Immunological Disorders of the Intestines Symposium Buenos Aires, Argentina
1996
What is refractory IBD and how can we manage it with medicine? Leiden IBD-DAG Symposium Leiden, Netherlands
1996
Overview of IBD: Current Concepts, Therapies, and Research Seminar for Nurses St. Paul, Minnesota
1996
Induction of remission in Crohns disease International Meeting - Crossing Borders in IBD Barcelona, Spain
1998
Budesonide controlled ileal release capsules once or twice daily in active Crohns disease. A placebo controlled study International Organization of Inflammatory Bowel Disease Annual Meeting Noordwick, Netherlands
1998
Ulcerative Colitis The Doctor in Focus Montreux, Switzerland
2000
Regional
13. Visiting ProfessorshipsButterworth Hospital Grand Rapids, Michigan
1985
Postgraduate Course in Medicine University of Southern Calfiornia School of Medicine Hawaii
1986
A Practical Guide of Topical and Oral 5-ASA Products with Treatment in Inflammatory Bowel Disease Cedar Sinai Medical Center Los Angeles, California
1993
MeritCare Medical Center and Dakota Medical Center Fargo, North Dakota
1993
Grand Rounds Presentation Division of Gastroenterology, Eastern Virginia School of Medicine Norfolk, Virginia
1994
Grand Rounds Presentation Division of Gastroenterology, University of Alberta Alberta, Canada
1994
GI Grand Rounds Division of Gastrenterology, St. Louis University St. Louis, Missouri
1995
Medical Grand Rounds University of South Dakota Sioux Falls, South Dakota
1995
Division of Gastroenterology, University of Wisconsin 1997
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Madison, Wisconsin
Division of Gastroenterology, Yale University New Haven, Connecticut
1998
Division of Gastroenterology, Case Western University Cleveland, Ohio
1999
Division of Gastroenterology, St. Louis University St. Louis, Missouri
1999
Division of Gastroenterology, University of Connecticut Farmington, Connecticut
1999
Division of Gastroenterology Case Western University Cleveland, Ohio
2000
14. Clinical Practice, Interests, and AccomplishmentsGastroenterology, with a primary interest in inflammatory bowel disease Internal Medicine
15. Research Interests
16. Educational Practice, Interests, and Accomplishments
17. Research Grants AwardedActive GrantsFederal
Consultant (MEthotrexate Response In Treatment of UC - MERIT-UC). Funded by National Institutes of Health. (U01 DK 92239)
08/15/2011 - 06/30/2017
IndustryCo-Investigator Amendment#1 - Replacement - CD INFORM: Investigating
Natalizumab through Further Observational Research and Monitoring in: Amendment#1- Replacement - CD INFORM: Investigating Natalizumab through Further Observational Research and Monitoring. Funded by Biogen Idec. (Protocol ELN100226-CD451)
11/05/2008 - 11/04/2013
Co-Investigator Millennium C13008 for ulcerative colitis / Crohn's disease. Funded by Millennium Pharmaceuticals, Inc. (C13008)
11/15/2008 - 11/14/2009
Co-Investigator SECURE / A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohns Disease. Funded by UCB Pharma, Inc. (Study C87075 Protocol RPCE08G1704)
05/01/2009 - 04/30/2019
Co-Investigator Developing a bowel damage for Crohns disease: looking beyond the mucosa. Funded by UCB Pharma, Inc.
01/01/2010 - 12/31/2010
Co-Investigator Prospective Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohns Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence (PREVENT). Funded by Janssen Services, LLC. (REMICADECRD3001)
11/01/2010 - 10/31/2011
Co-Investigator A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects with Crohns disease who are Anti-TNF Inadequate Responders (OPERA). Funded by Pfizer Inc. (Protocol
08/01/2011 - 07/31/2012
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
#A7281006)
Completed GrantsFederal
Co-Investigator Use of symbiotics to reduce urinary oxalate excretion. Funded by National Center for Complementary and Alternative Medicine. (R21 AT 02534)
09/2005 - 09/2009
FoundationCo-Investigator Measles Vaccination and Inflammatory Bowel Disease. Funded
by American College of Gastroenterology.07/1997 - 06/1998
Co-Investigator A Cross-Sectional Study of Inflammatory Bowl Disease Patients Receiving Azathioprine or 6-Mercaptopurine to Determine the Relationship Between Thiopurine Methyltransferase Activity, 6-Thioguanine Nucleotide Concentration, and Disease Status. Funded by American College of Gastroenterology.
07/1999 - 06/2000
Co-Investigator An Epidemiological Study of Microscopic Colitis: Incidence, Prevalence, Cancer Risk and Association with Cigarette Smoking. Funded by American College of Gastroenterology.
07/2002 - 06/2003
IndustryPrincipal Investigator
Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Asacol in the Treatment of Symptomatic Crohn's Colitis and Crohn's Ileocolitis. Funded by Norwich Eaton Pharmaceuticals/Proctor & Gamble Pharmaceuticals.
01/1989 - 01/1992
Principal Investigator
Bismuth Foam Enemas For the Treatment of Chronic Pouchitis. Funded by Tillotts Pharma AG (Switzerland).
01/1993 - 01/1996
Principal Investigator
Phase II Multicenter Study of Anti-TNF Chimeric Antibody (cA2) in the Treatment of Patients with Ulcerative Colitis. Funded by Centocor, Inc.
01/1994 - 01/1995
Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled Trial Of The Addition Of Bismuth Carbomer Foam Enemas To Standard Therapy For Treatment Of Ileal Pouchitis In Patients With Previous Protocoletomy And Ileal Pouch-Anal Anastomosis For Ulcerativ. Funded by Tillotts Pharma Ag. (Tillotts #1)
04/1994 - 02/1995
Principal Investigator
Phase II Multi-Center Study Of Chimeric Anti-TNF Monoclonal Antibody (cA2) In The treatment Of Patients With Ulcerative Colitis. Funded by Centocor Corporation. (Centocor #11)
06/1994 - 05/1995
Principal Investigator
Budesonide Controlled Ileal Relief Capsules Once or Twice Daily in Active Crohn's Disease. A Placebo Controlled Study. Funded by Astra Merck.
01/1995 - 01/1998
Principal Investigator
Safety, Tolerance, Pharmacokinetics And Pharmacodynamics Of Multiple doses Of Intravenous rhuIL-10(SCH 52000) In Patients With Steroid Refractory Crohn,s Disease. Funded by Schering-Plough Research Institute. (Schering #32)
02/1995 - 01/1996
Principal Investigator
Safety, Tolerance and Activity of Multiple Doses of Subcutaneous rHuLL-10 (SCH 52000) in Patients with Mildly to Moderately Active Ulcerative Colitis. Funded by Schering-Plough Research Institute. (SCHERING #35)
07/1995 - 01/1997
Principal Investigator
Safety, Tolerance and activity of Multiple Doses of Subcutaneous rHuLL-10 (SCH 52000) in patients with Mildly to Moderately Active Crohn's Disease. Funded by Schering-Plough Research
07/1995 - 01/1997
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Institute. (Schering #34)
Principal Investigator
Budesonide Controlled Ileal Release Capsules. Once or twice daily in active Crohn's disease placebo controlled study. Funded by Astra USA, Inc. (Astra #10)
10/1995 - 09/1996
Principal Investigator
Treatment of Gastroduodenal Crohn's Disease with Omeprazole: A Multicenter, Blinded, Randomized Placebo Controlled Trial. Funded by Astra Merck.
01/1996 - 01/1999
Principal Investigator
Budesonide Controlled Ileal Release Capsules as Maintenance Treatment in Crohn's Disease. A Placebo-Controlled Study. Funded by Astra USA, Inc. (Astra 15)
03/1996 - 03/1999
Principal Investigator
Safety, Tolerance and Efficacy of Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease in: Companion Protocol to C/195-152: Safety and Tolerance of Retreatment with Multiple Doses of Subcutaneous rHuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease. Funded by Schering-Plough Research Institute.
03/1996 - 02/2003
Principal Investigator
Companion Protocol to C/195-152: Safety and Tolerance of Retreatment with Multiple Doses of Subcutaneous rHuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease. Funded by Schering-Plough Research Institute. (Schering 41)
03/1996 - 09/2003
Principal Investigator
Proposal for the Development of Guidelines for Clinical Practice in Inflammatory Bowel Disease. Funded by Solvay. (Solvay #1)
04/1996 - 03/2003
Principal Investigator
Treatment of Gastroduodenal Crohn's Disease With Omeprazole: A Multicenter Controlled Trial. Funded by Astra Merck. (Astra #9)
05/1996 - 07/2000
Principal Investigator
Safety, Tolerance, and Efficacy of Treatment with Subcutaneous rHuIL-10 (SCH 52000) in subjects with Steroid-Dependent Crohn's Disease. Funded by Schering-Plough Research Institute. (Schering 62)
06/1998 - 05/1999
Principal Investigator
Open-Label, Two Stage Pilot Study to Determine the Study, Tolerability, Steady-State Pharmacokinetics and Potential Efficacy of Subcutaneous APL 2059 for Patients With Mild to Moderate Active Ulcerati. Funded by Axys Pharmaceuticals.
01/1999 - 01/2002
Principal Investigator
A Placebo Controlled Trial of Alendronate for the Prevention of Osteoporosis in Patients with Inflammatory Bowel Disease. Funded by Merck & Co., Inc.
01/1999 - 01/2002
Principal Investigator
Assessment of Ulcerative Colitis Disease Activity and Treatment Response-Time Using Scintigraphy. Funded by Solvay Pharmaceuticals.
01/2000 - 01/2002
Principal Investigator
Open-Label, Two-Stage Pilot Study to Determine the Safety, Tolerability, Steady-State Pharmacokinetics and Potential Efficacy of Subcutaneous APC 2059 for Patients with Mild to Moderate Active Ulcerative Colitis or Proctosigmoiditis. Funded by Axys Pharaceuticals, Inc. (AXYS 1)
01/2000 - 12/2003
Principal Investigator
Expression of hGRB in Ulcerative Colitis Patients Who are Refractory to Corticostreoids Compared to Patients who are Steroid Responsive? Funded by Astra Merck. (ASTRAZENECA #6)
02/2001 - 01/2003
Principal Safety and Efficacy of Two Dose Regimens of CB-1011 01/2002 - 12/2002
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Investigator (Medrozyprogesterone Acetate, MPA) in Patients with Active Crohn's Disease: A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial. Funded by InKine Pharmaceutical Company. (INKINE #1)
Principal Investigator
Late Onset IBD. Funded by Procter and Gamble. (PROCTER #23; 1A5347)
10/2004 - 09/2005
Program Director / Principal Investigator
Influence on Medical Therapy on Proximal Progression of Left-sided Ulcerative Colitis. Funded by Procter and Gamble. (Program ID#: 5956940)
11/2006 - 10/2009
Program Director / Principal Investigator
Efficacy of Oral Mesalamine in the Treatment of Crohn's Colities - A Retrospective Study. Funded by Procter and Gamble.
09/2007 - 08/2009
Co-Investigator Placebo-Controlled Trial of 5-aminosalicylic acid Enemas in Ulcerative Proctosigmoiditis. Funded by Reid Rowell Pharmaceuticals.
01/1983 - 01/1984
Co-Investigator Oral 5-aminosalicylic acid in the Treatment of Ulcerative Colitis, Collagenous Colitis and Crohn's Disease. Funded by Tillotts Labs (England) and Norwich Eaton Pharmaceuticals.
01/1984 - 01/1992
Co-Investigator Cyclosporine Enemas for Ulcerative Proctosigmoiditis. Oral Cyclosporine for Treatment of Crohn's Disease. Funded by Sandoz Pharmaceuticals.
01/1991 - 01/1992
Co-Investigator Randomized, Placebo-Controlled Trial of the Addition of the Trans-dermal Nicotine Patch to Current Therapy for Mildly to ModerateActive Ulcerative Colitis in Lifetime Non-Smokers and Ex-Smokers. Funded by ELAN Pharmaceuticals.
01/1992 - 01/1994
Co-Investigator An International Study to Assess Health Related Quality of Life and Its Predictors in Inflammatory Bowel Disease. Funded by Astra Pharmaceuticals. (Astra #8)
12/1995 - 11/1996
Co-Investigator Evaluation of ANCA, ASCA, and APA as Serologic Disease Markers in a Population Based Cohort of Patients with Ulcerative Colitis and Crohn's Disease. Funded by Prometheus Laboratories, Inc. (Prometheus 1)
10/1997 - 07/2000
Co-Investigator A Pharmacodynamic and Pharmacokinetic Study to Determine the Clinical Significance of Drug Interactions Between Azathioprine and Sulfasalazine or Pentasa in Patients with Inflammatory Bowl Disease. Funded by Procter and Gamble. (Proctor 10)
11/1998 - 10/2000
Co-Investigator Costs of Illness in Crohn's Disease: Comparison Between Clinical Phenotypes in: Costs of Illness om Crohn's Disease: Comparison Between Clinical Phenotypes. Funded by Schering-Plough Research Institute. (INTEGRATED 7)
04/1999 - 03/2003
Co-Investigator Determining the Clinical Outcome and Side Effects Associated with the Treatment of Patients with Crohn's Disease with the Anti-TNF Antibody, Infliximab. Funded by Centocor Corporation. (CENTOCOR 13)
06/1999 - 05/2003
Co-Investigator Registry of Crohn's Patients Some of Whom Have Been Treated with Remicade. Funded by Centocor Corporation. (TREAT-PHYSICIAN PARTICIPATION AGREEMENT)
11/1999 - 10/2009
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Co-Investigator A Randomized, Placebo-Controlled Trial of Alosetron in Microscopic Colitis. Funded by Glaxo Wellcome, Inc. (GLAXO #87)
06/2000 - 05/2002
Co-Investigator Therapeutic Effect of Lactic Acid Bacteria in Enteric Hyperoxaluria. Funded by VSL Pharmaceuticals. (VSL#2 1A4393)
01/2002 - 12/2006
Co-Investigator Effect of 5-Aminosalicylates on Progression of Indefinite or Low-Grade Dysplasia to Advanced Neoplasia in Ulcerative Colitis. Funded by Procter and Gamble. (PROCTER #22; 1A5232)
07/2004 - 07/2006
Co-Investigator A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Funded by Centocor Research & Development, Inc. (C0524T17)
06/2007 - 05/2008
Co-Investigator A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis in: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Funded by Centocor Research & Development, Inc. (C0524T18)
06/2007 - 01/2012
Co-Investigator A phase IV, multi-center, open-label study to assess clinical recurrence related to compliance with treatment with MMX mesalamine 2.4g/day given once daily for the maintenance of quiescent ulcerative colitis (UC). Funded by Shire Development, Inc. (SPD476-404)
06/2007 - 06/2008
Co-Investigator A Randomized, Double-Blind, Placebo-Controlled, Parallel Center Study to Investigator the Safety an Efficacy of CP-690,550 in Subjects with Moderate to Severe Crohn's Disease in: Pfizer CP-690,550. Funded by Pfizer Inc. (Protocol #3921043)
01/2008 - 01/2009
Co-Program Director / Principal Investigator
Abbott ABT-874 Protocol No. M10-222 in: Abbott ABT-874 Protocol Number M10-222. Funded by Abbott Laboratories. (M10-222)
01/2008 - 01/2010
Co-Program Director / Principal Investigator
Amendment#3-Replacement-Abbott ABT-874 Protocol Number M10-222 in: Abbott ABT-874 Protocol Number M10-222-A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy,. Funded by Abbott Laboratories. (M10-222)
01/2008 - 01/2010
Co-Program Director / Principal Investigator
Amendment#2-Replacement-Abbott ABT-874 Protocol Number M10-222-A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy, in: Amendment #2-Replacement-Abbott ABT-874 Protocol Number M10-222-A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy,. Funded by Abbott Laboratories. (M10-222)
01/2008 - 01/2010
Co-Program Novartis AIN457 Protocol Number CAIN457A2202. Funded by 01/2008 - 01/2009
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Director / Principal Investigator
Novartis.
Co-Investigator Lactoferrin as a Predictor of Early Relapse in Infammatory Bowel Disease in: Lactoferrin TechLab Budget. Funded by Techlab.
06/2008 - 06/2009
Co-Investigator Adalimumab Open-Label M10-223. Funded by Abbott Laboratories.
08/2008 - 07/2011
Co-Investigator Centocor CNTO 1275 Ustekinumab. Funded by Centocor Research & Development, Inc. (Protocol C0743T26)
08/2008 - 08/2009
Co-Investigator "C13006-A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis". Funded by Millennium Pharmaceuticals, Inc. (C13006)
09/2008 - 09/2009
Co-Investigator Millennium C13007 for Crohn's disease. Funded by Millennium Pharmaceuticals, Inc. (C13007)
09/2008 - 09/2009
Co-Investigator A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis. Funded by Shire Development, Inc. (Protocol No. SPD476-409)
09/2010 - 08/2011
Co-Investigator A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohns Disease in: CENTERPHASE: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohns Disease. Funded by Amgen. (Protocol No. 20090072 / Contract 136397)
12/2010 - 12/2011
Co-Investigator A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohns Disease in: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohns Disease. Funded by GlaxoSmithKline. (Protocol CCX114151)
01/2011 - 01/2012
Co-Investigator A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohns Disease in: C13011 A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohns Disease. Funded by Millennium Pharmaceuticals, Inc. (Protocol C13011 / Appendix Agreement # 222081)
02/2011 - 01/2012
Consultant Epidemiology, Severity, and Clinical Course of Crohn's Disease and Ulcerative Colitis in Olmsted County. Funded by Schering-Plough Research Institute. (Schering 36)
10/1995 - 12/1998
Mayo Clinic
-
TremaineCV.htm[4/8/2015 8:48:29 AM]
Principal Investigator
Pilot Study using Short Chain Fatty Acid Enemas in the Treatment of Ileoanal Pouchitis. Funded by Mayo Foundation Research Committee.
01/1989 - 01/1990
Principal Investigator
Prevention of Osteoporosis in IBD with Alendronate. Funded by CR Programs.
08/2000 - 07/2002
Co-Investigator A Dose Ranging Pharmacokinetic study of Nicotine and Nicotine-Carbomer Formulations in Healthy Human Volunteers Following Single dose IV and Delayed-Release Oral Administration. Funded by Mayo Rochester.
04/1996 - 03/1997
Co-Investigator Early Measles Virus Infection and Inflammatory Bowel Disease. Funded by Mayo Protocol.
03/1997 - 02/1999
Co-Investigator A Phase I Study to Determine the Optimum Dose and Dosing Schedule of Intravenous Azathioprine Loading to Decrease the Time to Response in Patients with Active, Steroid-Refractory Ulcerative Colitis. Funded by CR Programs.
10/1997 - 09/2000
Co-Investigator Colonic Motility in Ulcerative Colitis. Funded by CR Programs. 01/1998 - 12/1998
Co-Investigator A Pharmacodynamic and Pharmacokinetic Study to Determine the Clinical Significance of Drug Interactions Between Azathioprine and Sulfasalazine or Pentasa in Patients with Inflammatory Bowl Disease. Funded by Mayo CR20 Funding.
12/1998 - 11/1999
Co-Investigator Cross-Sect'l Study, Inflammatory Bowel Disease Pts Recv'g Azathioprine/6-Mercaptopurine & Relationship b/t Thiopurine Methyltransferase Activity, 6-Thioguanine Nucleotide Concentration, Disease Status inc Leukopenia. Funded by CR Programs.
03/1999 - 12/2000
Co-Investigator Imaging Small Bowel Crohn's Disease: A Feasibility Study Comparing Optimized CT with Small Bowel Follow Through Examinations. Funded by CR Programs.
10/1999 - 09/2000
18. Patents
Title Patent Number Date filed Date issued
William J. Tremaine, MD Page of
RE-AIMS 04/08/2015
Local DiskTremaineCV.htm